Establishment of a new method for detection of TROP2-positive circulating tumor cells in breast cancer.
Uloženo v:
| Název: | Establishment of a new method for detection of TROP2-positive circulating tumor cells in breast cancer. |
|---|---|
| Autoři: | Wang A; Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Fujian Provincial Key Laboratory of Brain Aging and Neurodegenerative Diseases, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.; CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China.; The First Affiliated Hospital, Fujian Medical University, Fuzhou, China., Zeng P; Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Fujian Provincial Key Laboratory of Brain Aging and Neurodegenerative Diseases, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.; CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China., Ma T; Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Fujian Provincial Key Laboratory of Brain Aging and Neurodegenerative Diseases, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.; CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China., Shi H; Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Fujian Provincial Key Laboratory of Brain Aging and Neurodegenerative Diseases, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.; CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China., Li R; CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China.; Department of Epidemiology, Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, China., Xu H; CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China.; Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China., Feng Y; CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China.; Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China., Liu Q; Nanopep Biotech Corporation, Beijing, China., Wang M; Nanopep Biotech Corporation, Beijing, China., Chen T; Key Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing, China., Hu Z; Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Fujian Provincial Key Laboratory of Brain Aging and Neurodegenerative Diseases, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China. huzy@nanoctr.cn.; CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China. huzy@nanoctr.cn.; School of Nanoscience and Technology, Sino-Danish College, University of Chinese Academy of Sciences, Beijing, China. huzy@nanoctr.cn.; School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan, China. huzy@nanoctr.cn., Wang R; The First Affiliated Hospital, Fujian Medical University, Fuzhou, China. 13960758357@fjmu.edu.cn., Zhou Y; Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Fujian Provincial Key Laboratory of Brain Aging and Neurodegenerative Diseases, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China. zhouying@fjmu.edu.cn.; CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China. zhouying@fjmu.edu.cn., Hao X; Department of General Surgery, First Medical Center of Chinese PLA General Hospital, Beijing, China. hxp307@163.com. |
| Zdroj: | BMC cancer [BMC Cancer] 2025 Nov 21; Vol. 25 (1), pp. 1797. Date of Electronic Publication: 2025 Nov 21. |
| Způsob vydávání: | Journal Article |
| Jazyk: | English |
| Informace o časopise: | Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: London : BioMed Central, [2001- |
| Výrazy ze slovníku MeSH: | Neoplastic Cells, Circulating*/metabolism , Neoplastic Cells, Circulating*/pathology , Breast Neoplasms*/pathology , Breast Neoplasms*/diagnosis , Breast Neoplasms*/blood , Breast Neoplasms*/metabolism , Antigens, Neoplasm*/metabolism , Cell Adhesion Molecules*/metabolism , Biomarkers, Tumor*/metabolism, Humans ; Female ; Epithelial Cell Adhesion Molecule/metabolism ; Cell Line, Tumor ; Magnetite Nanoparticles/chemistry |
| Abstrakt: | Competing Interests: Declarations. Ethics approval and consent to participate: All procedures conducted in this study using human data were in accordance with the Declaration of Helsinki. This study was reviewed and approved by the Ethics Committees of the First Medical Center of Chinese PLA General Hospital (2022-2-9-2). All patients and healthy individuals had given written informed consent. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. Trophoblast cell surface antigen 2 (TROP2) overexpression has been demonstrated in several tumor types, including breast cancer (BC). Circulating tumor cells (CTCs) offer a non-invasive, dynamic and real-time detection method. The detection of TROP2 expression in CTCs is significant for predicting BC progression, prognosis and the efficacy of targeted therapy. A quantitative analysis method for TROP2 of CTCs was established using our established TUMORFISHER detection platform based on epithelial cell adhesion molecule (EpCAM), and a new magnetic nanoparticle with TROP2 as the trapping target was developed, named TROP2@MNPs. The developed quantitative analysis of TROP2 was an effective method for accurately identifying the expression of TROP2 in BC cells and CTCs from BC patients, which was consistent with the data obtained by immunohistochemical (IHC) analysis. The established TROP2@MNPs could specifically capture TROP2-positive BC cells, and the capture efficiency was closely related to the expression of TROP2 in CTCs. Notably, the TROP2-based enrichment strategy was found to capture TROP2-expressing CTCs that were missed by the EpCAM-based enrichment strategy. The TROP2-targeting CTC capture platform, TROP2@MNPs, could serve as a liquid biopsy of TROP2 expression in BC patients, providing an important reference for further research on CTC-related diagnosis and individualised treatment employing TROP2-targeting drugs. (© 2025. The Author(s).) |
| References: | Breast Cancer Res Treat. 2023 Jul;200(2):281-291. (PMID: 37227611) Cancers (Basel). 2022 Feb 27;14(5):. (PMID: 35267548) NPJ Breast Cancer. 2021 May 20;7(1):56. (PMID: 34016991) Chin J Cancer Res. 2018 Jun;30(3):315-326. (PMID: 30046226) NPJ Breast Cancer. 2021 Oct 28;7(1):141. (PMID: 34711841) J Clin Oncol. 2005 Mar 1;23(7):1420-30. (PMID: 15735118) Biomark Res. 2024 Aug 13;12(1):82. (PMID: 39135109) Exploration (Beijing). 2023 Jul 02;3(4):20220124. (PMID: 37933240) Oncotarget. 2015 Sep 8;6(26):22496-512. (PMID: 26101915) Cancers (Basel). 2021 Sep 15;13(18):. (PMID: 34572846) J Clin Oncol. 2017 Jul 1;35(19):2141-2148. (PMID: 28291390) N Engl J Med. 2004 Aug 19;351(8):781-91. (PMID: 15317891) Cell. 2023 Apr 13;186(8):1708-1728. (PMID: 36931265) Med Sci Monit. 2018 May 31;24:3637-3643. (PMID: 29849016) Exploration (Beijing). 2022 Apr 16;2(3):20210222. (PMID: 37323704) Biomedicines. 2021 Nov 01;9(11):. (PMID: 34829820) CA Cancer J Clin. 2024 May-Jun;74(3):229-263. (PMID: 38572751) Front Oncol. 2022 Apr 28;12:866293. (PMID: 35574364) Pharmacol Ther. 2022 Nov;239:108296. (PMID: 36208791) Exp Hematol Oncol. 2023 Jan 9;12(1):3. (PMID: 36624542) Clin Cancer Res. 1999 Aug;5(8):1950-60. (PMID: 10473071) Front Oncol. 2022 Aug 01;12:890248. (PMID: 35978805) BMC Med. 2022 Mar 11;20(1):90. (PMID: 35272686) Exploration (Beijing). 2023 Jul 20;3(5):20230007. (PMID: 37933287) Cancers (Basel). 2023 Mar 13;15(6):. (PMID: 36980630) Exploration (Beijing). 2023 Oct 28;3(6):20230070. (PMID: 38264683) Cancer. 2008 Nov 1;113(9):2422-30. (PMID: 18785255) Exploration (Beijing). 2024 Jan 23;4(4):20230124. (PMID: 39175886) Cell. 2009 Nov 25;139(5):871-90. (PMID: 19945376) Breast. 2016 Oct;29:192-201. (PMID: 27521224) Front Oncol. 2021 Feb 04;10:609275. (PMID: 33614493) Breast. 2017 Apr;32:119-125. (PMID: 28157583) J Mater Chem B. 2014 Jul 14;2(26):4080-4088. (PMID: 32261739) Biochim Biophys Acta Rev Cancer. 2023 Jul;1878(4):188902. (PMID: 37121444) Nat Rev Drug Discov. 2023 Feb;22(2):101-126. (PMID: 36344672) Proc Natl Acad Sci U S A. 1981 Aug;78(8):5147-50. (PMID: 7029529) |
| Grant Information: | XRCZX2017020, XRCZX2019005 Research Foundation for Advanced Talents of Fujian Medical University; 32471456, 32027801, 31870992, 21775031 National Natural Science Foundation of China; 32471456, 32027801, 31870992, 21775031 National Natural Science Foundation of China; GJHZ2094 CAS-JSPS; KFJ-STS-ZDTP-079 Science and Technology Service Network Initiative of the Chinese Academy of Sciences; 2022J01203 the Natural Science Foundation of Fujian Province |
| Contributed Indexing: | Keywords: Breast cancer; Circulating tumor cell; Liquid biopsy; Magnetic nanoparticle; TROP2 |
| Substance Nomenclature: | 0 (Antigens, Neoplasm) 0 (Cell Adhesion Molecules) 0 (TACSTD2 protein, human) 0 (Biomarkers, Tumor) 0 (Epithelial Cell Adhesion Molecule) 0 (EPCAM protein, human) 0 (Magnetite Nanoparticles) |
| Entry Date(s): | Date Created: 20251122 Date Completed: 20251122 Latest Revision: 20251125 |
| Update Code: | 20251125 |
| PubMed Central ID: | PMC12636157 |
| DOI: | 10.1186/s12885-025-14184-y |
| PMID: | 41272532 |
| Databáze: | MEDLINE |
Full Text 
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | Competing Interests: Declarations. Ethics approval and consent to participate: All procedures conducted in this study using human data were in accordance with the Declaration of Helsinki. This study was reviewed and approved by the Ethics Committees of the First Medical Center of Chinese PLA General Hospital (2022-2-9-2). All patients and healthy individuals had given written informed consent. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.<br />Trophoblast cell surface antigen 2 (TROP2) overexpression has been demonstrated in several tumor types, including breast cancer (BC). Circulating tumor cells (CTCs) offer a non-invasive, dynamic and real-time detection method. The detection of TROP2 expression in CTCs is significant for predicting BC progression, prognosis and the efficacy of targeted therapy. A quantitative analysis method for TROP2 of CTCs was established using our established TUMORFISHER detection platform based on epithelial cell adhesion molecule (EpCAM), and a new magnetic nanoparticle with TROP2 as the trapping target was developed, named TROP2@MNPs. The developed quantitative analysis of TROP2 was an effective method for accurately identifying the expression of TROP2 in BC cells and CTCs from BC patients, which was consistent with the data obtained by immunohistochemical (IHC) analysis. The established TROP2@MNPs could specifically capture TROP2-positive BC cells, and the capture efficiency was closely related to the expression of TROP2 in CTCs. Notably, the TROP2-based enrichment strategy was found to capture TROP2-expressing CTCs that were missed by the EpCAM-based enrichment strategy. The TROP2-targeting CTC capture platform, TROP2@MNPs, could serve as a liquid biopsy of TROP2 expression in BC patients, providing an important reference for further research on CTC-related diagnosis and individualised treatment employing TROP2-targeting drugs.<br /> (© 2025. The Author(s).) |
|---|---|
| ISSN: | 1471-2407 |
| DOI: | 10.1186/s12885-025-14184-y |